Department of Medicine Faculty Profile

Olatoyosi Odenike
Section of Hematology / Oncology
Assistant Professor of Medicine

e-mail: todenike@medicine.bsd.uchicago.edu
Referring Physician Access Line: 1-877-DOM-2730

Training:

Degree	Year	Institution	Area
MD	1988	The University of Ibadan	Medicine
Residency	1994	University of Illinois	Internal Medicine and Pediatrics
Fellowship	1997	The University of Chicago	Hematology/Oncology

Academic Interests:

Dr. Odenike’s research is focused on the development of novel therapeutic agents for the treatment of acute and chronic leukemias, and chronic myeloproliferative diseases, with the ultimate goal of improving treatment options for patients with these diseases. She is the principal investigator on a number of clinical trials investigating molecularly targeted agents in this patient population. These clinical trials also integrate laboratory studies to evaluate the effect that these agents are having on cancer cells.

Clinical Interests:

Acute and chronic leukemias, chronic myeloproliferative diseases, myelodysplastic syndrome, lymphomas, stem cell transplantation.

Representative Publications:

Odenike OM, Sobecks RM, Janisch LA, Huo D, Zimmerman TM, Daugerty CK, Ratain MJ, Larson RA: Phase I study of Gemcitabine and Cladribine in Patients with Advanced Hematologic Malignancies. Cancer Chemother Pharmacology 2004 Dec;54(6):553-61
Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Odenike T, Stock W. Irreversible Myelosuppression after Fludarabine-Melphalan conditioning. Observations in Patients with Graft Rejection. Letter to the editor, Blood 2004 Jun 1;103(11)4373-4.
Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Housman D, Doggett N, Rowley JD, Zeleznik-Le NJ: MLL is fused to CBP, a histone-acetyl-transferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc.Natl. Acad. Sci. USA, 94:8732-8737,1997.
Rowley JD, Reshmi S, Sobulo OM, Raimondi S, Schneider N, Barredo J, Schlegelberger B, Behm F, Doggett N, Borrow J, Zeleznik-Le NJ: All patients with the t(11;16)(q23;p13.3) which involves MLL and CBP have treatment-related hematologic disorders. Blood, 90:535-541,1997.
Odenike OM, Michaelis L, Stock W: Acute Lymphoblastic Leukemia. In: Oncology- An Evidence-Based Approach. - In Press.